Successful ruxolitinib administration for a patient with steroid‐refractory idiopathic pneumonia syndrome following hematopoietic stem cell transplantation: A case report and literature review

Abstract

Abstract Idiopathic pneumonia syndrome (IPS) is an acute lung complication observed after the early posthematopoietic stem cell transplantation (HSCT) period. Ruxolitinib was effective for a patient with myelodysplastic syndrome who developed severe IPS after second HSCT. No severe adverse effects were observed. Ruxolitinib may be an alternative choice for HSCT‐related IPS.

Keywords

• graft‐versus‐host disease
• hemophagocytic lymphohistiocytosis
• idiopathic pneumonia syndrome
• myelodysplastic syndrome
• ruxolitinib